Latest Mammaprint Stories
IRVINE, California and AMSTERDAM, July 21, 2011 /PRNewswire/ -- Agendia, a global innovator in molecular cancer diagnostics, announced today that, together with thought-leading collaborators in clinical centers and translational research groups, it has launched the RATHER (Rational Therapy for Breast Cancer) and COLTHERES (Colon Cancer and Therapeutics) consortiums.
CHICAGO, and ANN ARBOR, Mich., June 3, 2011 /PRNewswire/ -- Everist Genomics today announced updated results from a study of its OncoDefender-CRC assay, a molecular prognostic test for early-stage colorectal cancer patients, will be presented at the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held June 3-7, 2011, in Chicago. (Logo: http://photos.prnewswire.com/prnh/20110110/NY26865LOGO) OncoDefender-CRC examines expression levels of a panel of genes...
Researchers from Virginia Commonwealth University Massey Cancer Center have discovered a new biomarker related to the body's immune system that can predict a breast cancer patients' risk of cancer recurrence.
Development of a predictive test that included genomic signatures that indicated chemoresistance, chemosensitivity and endocrine sensitivity for women with newly diagnosed breast cancer identified patients with a high probability of survival following chemotherapy.
REDWOOD CITY, Calif. and ST. GALLEN, Switzerland, March 17, 2011 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced results from nine studies utilizing the Oncotype DXÂ® test in early-stage breast cancer patients at the 12th Annual St.
IRVINE, California and AMSTERDAM, February 23, 2011 /PRNewswire/ -- Agendia, a world leader in molecular cancer diagnostics, today announced that the company has received its fifth U.S.
SAN FRANCISCO and ANN ARBOR, Mich., Jan.
IRVINE, California, and AMSTERDAM, December 22, 2010 /PRNewswire/ -- - This release was originally scheduled for distribution on December 20, 2010, 17.00 CET.
IRVINE, California and AMSTERDAM, December 15, 2010 /PRNewswire/ -- - Second Independent Validation Study of ColoPrint Selected for Oral Presentation and Press Conference at ASCO GI in January 2011 Agendia, a world leader in molecular cancer diagnostics, announced today that together with principal investigators from Spain, the UK, and the Netherlands, it has published the first independent validation study of its colon cancer recurrence test "ColoPrint" in the Journal of...
IRVINE, California and AMSTERDAM, October 19, 2010 /PRNewswire/ -- Agendia, a world leader in molecular cancer diagnostics, announced today that it has established a contract with leading insurance provider Humana to reimburse for the company's MammaPrint test.
- Having no light.
- Of or relating to the region of a body of water that is not reached by sunlight and in which photosynthesis is unable to occur.